Structure Therapeutics Future Growth
Future criteria checks 2/6
Structure Therapeutics's earnings are forecast to decline at 27.6% per annum while its annual revenue is expected to grow at 32.3% per year. EPS is expected to grow by 1% per annum. Return on equity is forecast to be -30.7% in 3 years.
Key information
-27.6%
Earnings growth rate
1.0%
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 32.3% |
| Future return on equity | -30.7% |
| Analyst coverage | Good |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -244 | -269 | -198 | 6 |
| 12/31/2025 | 63 | -102 | -201 | -194 | 8 |
| 12/31/2024 | N/A | -141 | -140 | -107 | 8 |
| 9/30/2024 | N/A | -111 | -104 | -102 | N/A |
| 6/30/2024 | N/A | -100 | -105 | -103 | N/A |
| 3/31/2024 | N/A | -98 | -96 | -93 | N/A |
| 12/31/2023 | N/A | -90 | -82 | -79 | N/A |
| 9/30/2023 | N/A | -77 | -71 | -70 | N/A |
| 6/30/2023 | N/A | -66 | -60 | -60 | N/A |
| 3/31/2023 | N/A | -58 | -53 | -53 | N/A |
| 12/31/2022 | N/A | -53 | -46 | -46 | N/A |
| 9/30/2022 | N/A | -56 | -45 | -45 | N/A |
| 12/31/2021 | N/A | -44 | -33 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GPCR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GPCR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GPCR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GPCR's revenue (32.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: GPCR's revenue (32.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GPCR is forecast to be unprofitable in 3 years.